279 related articles for article (PubMed ID: 23900716)
1. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Wöll S; Schlitter AM; Dhaene K; Roller M; Esposito I; Sahin U; Türeci Ö
Int J Cancer; 2014 Feb; 134(3):731-9. PubMed ID: 23900716
[TBL] [Abstract][Full Text] [Related]
2. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression.
Park S; Shin K; Kim IH; Hong T; Kim Y; Suh J; Lee M
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629433
[TBL] [Abstract][Full Text] [Related]
5. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
6. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
7. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Kayikcioglu E; Yüceer RO
Medicine (Baltimore); 2023 Feb; 102(6):e32882. PubMed ID: 36820561
[TBL] [Abstract][Full Text] [Related]
8. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
9. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.
Welsch T; Keleg S; Bergmann F; Bauer S; Hinz U; Schmidt J
Pancreas; 2009 Nov; 38(8):968-76. PubMed ID: 19672209
[TBL] [Abstract][Full Text] [Related]
10. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases.
Hansel DE; House MG; Ashfaq R; Rahman A; Yeo CJ; Maitra A
Int J Gastrointest Cancer; 2003; 33(2-3):141-7. PubMed ID: 14716063
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm.
Sanada Y; Hirose Y; Osada S; Tanaka Y; Takahashi T; Yamaguchi K; Yoshida K
Anticancer Res; 2010 Jul; 30(7):2995-3003. PubMed ID: 20683045
[TBL] [Abstract][Full Text] [Related]
12. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
13. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
Sahin U; Koslowski M; Dhaene K; Usener D; Brandenburg G; Seitz G; Huber C; Türeci O
Clin Cancer Res; 2008 Dec; 14(23):7624-34. PubMed ID: 19047087
[TBL] [Abstract][Full Text] [Related]
14. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.
Kawanishi A; Hirabayashi K; Yamada M; Takanashi Y; Hadano A; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
J Clin Pathol; 2017 Jul; 70(7):619-624. PubMed ID: 27980052
[TBL] [Abstract][Full Text] [Related]
16. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes.
Wagner P; Gass P; Pöschke P; Eckstein M; Gloßner L; Hartmann A; Beckmann MW; Fasching PA; Ruebner M; Emons J; Erber R
Virchows Arch; 2024 Feb; ():. PubMed ID: 38326579
[TBL] [Abstract][Full Text] [Related]
17. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
18. Expression of claudin-5 in canine pancreatic acinar cell carcinoma - An immunohistochemical study.
Jakab C; Rusvai M; Gálfi P; Halász J; Kulka J
Acta Vet Hung; 2011 Mar; 59(1):87-98. PubMed ID: 21354944
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]